MRI-Based Classification Systems Combined with Serum CA125 for Predicting Symptom Recurrence After Ultrasound-Guided High-Intensity Focused Ultrasound Ablation Surgery for Adenomyosis: A Retrospective Cohort Study

Adenomyosis, a benign estrogen-dependent gynecological disorder predominantly affecting perimenopausal women (40–50 years), is pathologically characterized by the ectopic invasion of endometrial glands and stroma into the myometrium, typically manifesting as debilitating dysmenorrhea and menorrhagia. 1 , 2 Recently, ultrasound-guided high-intensity focused ultrasound ablation (FUAS) has been recognized as a revolutionary non-invasive therapeutic modality for adenomyosis, providing significant advantages in uterine preservation while maintaining therapeutic efficacy. 3 Despite these advancements, clinical observations suggest that approximately 20–30% of patients experience disease recurrence following FUAS treatment, with a median relapse interval of 12 months. 4 This underscores the urgent need for reliable predictive biomarkers to optimize patient selection and guide treatment strategies. However, robust indicators for predicting post-FUAS symptom recurrence remain an unresolved challenge in clinical practice. The tumor marker cancer antigen (CA) 125 has emerged as a potentially valuable biomarker in this context. 5 , 6 A large number of studies have demonstrated that the serum CA125 level significantly elevates in adenomyosis patients compared with those with uterine fibroids (P<0.01), 7 , 8 and particularly pronounced elevation could be observed in diffuse-type versus focal adenomyosis. 5 , 9 Although preliminary evidence suggests that CA125 may have predictive value for symptom recurrence following FUAS, 5 its standalone clinical utility has been limited by suboptimal sensitivity and specificity. 5 , 8 , 9 Concurrently, advancements in magnetic resonance imaging (MRI) technology have established it as the gold standard for preoperative adenomyosis assessment prior to FUAS treatment. 10 , 11 Contemporary high-resolution MRI enables precise evaluation of key pathological features including junctional zone thickness, lesion vascularity, and myometrial involvement patterns. 11 Our previous study showed that based on classification of Kobayashi H criteria, patients had different clinical symptom stratified by myometrial involvement patterns. 12 , 13 Recent investigations have begun to explore the prognostic potential of MRI characteristics, with particular attention being paid to their correlation with treatment outcomes. 3 , 14 Nevertheless, current imaging-based studies have neither elucidated the mechanisms underlying symptom recurrence nor established comprehensive predictive models integrating both imaging and biochemical markers. Given the complementary strengths of CA125 as a biomarker of inflammatory activity and MRI as a tool for detailed anatomical characterization, we hypothesized that combining these modalities would improve the prediction of symptom recurrence after FUAS. Therefore, this study aimed to investigate the combined predictive value of preoperative serum CA125 levels and MRI-based classification systems for symptom recurrence following FUAS in patients with adenomyosis. By developing a dual-modality prognostic framework, we sought to enable more accurate risk stratification, inform personalized therapeutic decisions, and ultimately improve long-term patient outcomes.

In this retrospective cohort study, we analyzed 502 consecutive patients with MRI-confirmed adenomyosis treated with FUAS from June 2017 to March 2021. Patients were stratified into recurrence group (n=133) and non-recurrence group (n=369). In addition, our previous study showed Kobayashi H ’ s classification associated with symptom of adenomyosis, 12 hence, patients were categorized into two subgroups based on the lesion size of uterine wall in MRI: the lesion size of uterine wall ≥2/3 group (n=446) and the lesion size of uterine wall <2/3 group (n=56). Inclusion criteria: (1) MRI diagnosis of adenomyosis; (2) preoperative CA125 testing; (3) underwent FUAS; (4) complete follow-up data. Exclusion criteria: (1) coexisting uterine fibroids or malignancy; (2) inflammatory disease within 7 days; (3) previous treatment within 6 months; (4) incomplete data. The measurements of uterine and lesion dimensions across all meridians, conjugate zone thickness, and subcutaneous adipose tissue thickness were performed following the standardized protocols established by expert consensus. The MRI diagnostic criteria for adenomyosis were as follows: (1) a junctional zone maximum thickness (JZmax) exceeding 12 mm, (2) a JZmax-to-myometrial thickness ratio ≥40%, and (3) a difference in junctional zone maximum thickness >5 mm between the thickest and thinnest regions. Using a blinded assessment protocol, the quantitative measurements were independently performed by two imaging physicians (with ≥10 years of experience) and one obstetrician-gynaecologist (with ≥10 years of experience) with the title of deputy director or above. 3 , 15 Inter-rater reliability was established upon concordance analysis, where consistent measurements between the first two physicians were directly adopted for data analysis. In cases of discrepancies in measurements, a third independent evaluator was consulted to resolve the differences, and the final consensus measurements were incorporated into the dataset after thorough discussion and agreement among all the three evaluators. 3 The formula for calculating the uterine volume and lesion volume in adenomyosis was 0.52*long diameter*anteroposterior diameter*transverse diameter. The MRI-based classification systems of adenomyosis referred to two of our previous papers. 3 , 12 From August 2021 to December 2022, 502 patients were entered for follow-up observation, including whether dysmenorrhea and menorrhagia recurred, ie, whether dysmenorrhea recurred or not, and whether menorrhagia recurred or not. The primary outcome was symptom recurrence, defined as patient-reported dysmenorrhea and/or menorrhagia occurring at least 12 months after a symptom-free interval of ≥3 months post-FUAS. 5 Follow-up included on-site follow-up or telephone completion of questionnaires (for patients who lived far away and chose local follow-up). All pelvic MRI examinations were conducted using the 1.5 Tesla scanners with standardized protocols, including turbo spin-echo T2-weighted imaging and single-shot echo-planar diffusion-weighted imaging sequences, following the established methodology (Brown et al 15 ). Two imaging physicians (ZJ, with 10 years of experience; JZ, with 11 years of experience) and one gynecologist (YT, with 11 years of experience) were invited to individually reclassify adenomyosis according to the classification of Kobayashi H criteria. 12 The classification process followed rigorous methodology below: 1) each reviewer independently assessed all the cases; 2) initial concordance between any two reviewers was accepted for analysis; 3) discordant cases underwent tertiary review with consensus discussion; and 4) final classifications required agreement from at least two specialists. Quality Assurance Measures were as follows: 1) the classification schemes were detailed as previous study; 12 2) every case underwent evaluation by at least two reviewers; 3) final determinations reflected the complete inter-rater consensus; and 4) validation procedures maintained identical standards across different cohorts. Serum CA125 levels were quantified using a standardized two-step immunoassay at our central laboratory, with samples collected within 24 h pre-FUAS and transported at ambient temperature following the established protocols. 5 , 6 The FUAS treatment was performed using the JC200 Focused Ultrasound Tumor Therapeutic System (Chongqing Haifu Medical Technology Co., Ltd., China) in strict accordance with manufacturer’s guidelines. 16 During the procedure, critical treatment parameters including sonication time and average power output were systematically recorded. The ablation volume was calculated using the ellipsoid volume formula (V = 4/3πABC), where A, B, and C were consistent with the lesion’s longitudinal, transverse, and anteroposterior diameters, respectively. 17 Treatment efficacy was quantitatively assessed through the non-perfused volume (NPV) ratio, derived from the formula (NPV/adenomyosis volume) × 100%, by utilizing the dedicated analysis software provided by the manufacturer. 18 To ensure measurement accuracy, three independent operators (ZJ, JZ, and YT) performed blinded assessments of both target lesion dimensions and non-enhanced regions. 12 A consensus-based approach was implemented for result validation: concordant measurements from any two operators were accepted, while discordant results underwent tertiary review. All patients underwent the standardized 24-h post-procedural monitoring for immediate treatment evaluation and safety assessment. Continuous variables were indicated as mean ± standard deviation, while categorical data were presented as proportions. Body mass index (BMI) was dichotomized at 24 kg/m 2 . 19 Comparative analyses between recurrence and non-recurrence groups were performed using independent samples t-tests for continuous variables (including age, BMI, serum CA125 levels, adipose tissue thickness, lesion-to-sacrococcygeal distance, uterine/lesion volumes, ablation parameters, and NPV) and by chi-square tests for categorical variables (dysmenorrhea/menorrhagia status, uterine position, and lesion location). Univariate and multivariate logistic regression were performed to identify predictors of recurrence (age, dysmenorrhea, CA125 levels, T2WI signal intensity, grayscale variation, and GnRH-a/LNG-IUS therapy) and symptom recurrence, stratified by lesion extent (≥2/3 vs <2/3 myometrial involvement). The results were reported as adjusted odds ratios (ORs) with 95% confidence intervals. Variables with P<0.10 in univariate analysis were entered into multivariate models. The predictive performance of preoperative CA125 was assessed using receiver operating characteristic (ROC) curve analysis, with optimal cutoff values determined for the overall cohort and lesion-size subgroups. Time-to-recurrence was analyzed using Kaplan–Meier curves and Cox proportional hazards regression. All analyses were conducted using SPSS 22.0 (IBM Corp.), with two-tailed P-value <0.05 indicating statistical significance.

The total cohort comprised 502 adenomyosis patients with a median follow-up period of 24 months (range, 2–51 months). Comparative analysis revealed significant differences between recurrence (n=133, 26.5%) and non-recurrence (n=369, 73.5%) groups ( Table 1 ). 5 Patients experiencing symptom recurrence demonstrated (1) significantly higher preoperative serum CA125 levels (median 71.5 vs 51.14 U/mL, P<0.001), (2) younger mean age (P<0.001), and (3) higher prevalence of clinically relevant features including dysmenorrhea (P<0.05), extensive myometrial involvement (≥2/3 uterine wall thickness, P<0.05), diffuse grayscale changes during FUAS (P<0.05), and receipt of FUAS monotherapy (P<0.05). Table 1 Comparison of Clinical Features of Adenomyosis Between Recurrence Group and Non- Recurrence Group 5 Variable Total Group (n=502) Recurrence Group (n=133) Non Recurrence Group (n=369) Test Value P Age (years) 43.7±5.3 42.3±5.4 44.3±5.1 −3.652 24 209 (41.6) 48 (36.1) 161 (43.6)  ≤24 293 (58.4) 85 (63.9) 208 (56.4) Dysmenorrhea before FUAS 11.050 <0.001  Yes (%) 381 (75.9) 115 (86.5) 266 (72.1)  No (%) 121 (24.1) 18 (13.5) 103 (27.9) Menorrhagia before FUAS 2.595 0.107  Yes (%) 272 (54.2) 80 (60.2) 192 (52.0)  No (%) 230 (45.8) 53 (39.8) 177 (48.0) Uterus location 0.476 0.788  Anterior (%) 292 (58.2) 74 (55.7) 218 (59.1)  Posterior (%) 192 (38.2) 49 (36.8) 143 (38.8)  Neutral (%) 18 (3.6) 10 (7.5) 8 (2.1) Lesion size of uterine wall 4.824 0.028  ≥2/3 446 (88.8) 125 (94.0) 321 (87.0)  <2/3 56 (11.2) 8(6.0) 48 (13.0) Adenomyosis location 3.070 0.381  Anterior (%) 152 (30.3) 34 (25.6) 118 (32.0)  Posterior (%) 287 (57.1) 78 (58.6) 209 (56.6)  Fundus (%) 41 (8.2) 13 (9.8) 28 (7.6)  Anterior-Posterior (%) 22 (4.4) 8 (6.0) 14 (3.8) T2WI hyper-intensity 0.004 0.952  Yes (%) 102 (20.3) 27 (20.3) 74 (20.1)  No (%) 400 (79.7) 106 (79.7) 295 (79.9) Subcutaneous fat thickness (mm) 19.3±9.3 18.8±7.5 19.5±9.6 −0.717 0.474 Distance(mm) 24.1±14.8 24.0±15.2 24.1±14.7 −0.055 0.956 Uterus volume (cm3) 231.3±124.5 248.6±128.2 225.1±122.7 1.855 0.064 Adenomyosis volume (cm3) 53.6±55.7 61.4±53.4 50.8±56.4 1.839 0.067 Serum CA125 (U/mL) 55.8 (29.9, 106.4) 71.5 (58.9, 134.2) 51,4 (24.1, 111.8) −4.401 <0.001 Sonication time(s) 391.0±274.2 405.4±272.9 386.2±274.9 0.695 0.488 Average sonication power (s/h) 431.1±194.6 442.2±329.3 426.9±111.7 0.526 0.600 Grayscale change 4.355 0.037  Diffusion (%) 295 (58.8) 68 (51.1) 227 (61.5)  Single (%) 207 (41.2) 65 (48.9) 142 (38.5) NPV ratio (%) 72.0±26.0 69.9±24.7 74.3±23.8 −1.807 0.071 Treatment methods 10.436 0.001  FUAS (%) 253 (50.4) 83 (61.5) 170 (40.9)  FUAS+ (%) 249 (49.6) 50 (38.5) 199 (59.1) Abbreviations : BMI, body mass index; CA125, cancer antigen 125; T2WI, T2-weighted magnetic resonance imaging; distance, distance from the posterior surface of the adenomyosis lesion to the sacrum. FUAS, focused ultrasound ablation surgery; NPV, non-perfusion volume; FUAS+, with post-FUAS gonadotropin-releasing hormone/Levonorgestrel-releasing intrauterine system. Comparison of Clinical Features of Adenomyosis Between Recurrence Group and Non- Recurrence Group 5 Abbreviations : BMI, body mass index; CA125, cancer antigen 125; T2WI, T2-weighted magnetic resonance imaging; distance, distance from the posterior surface of the adenomyosis lesion to the sacrum. FUAS, focused ultrasound ablation surgery; NPV, non-perfusion volume; FUAS+, with post-FUAS gonadotropin-releasing hormone/Levonorgestrel-releasing intrauterine system. In the subgroup of patients with adenomyosis involving ≥2/3 of the uterine wall thickness, adenomyosis volume, uterus volume and serum CA125 levels were significantly higher than those in the subgroup of patients with adenomyosis involving <2/3 of the uterine wall thickness ( Supplementary Table 1 and Table 2 , P<0.05). The example of Kobayashi H ’ s classification was shown in Figure 1 . Table 2 Clinicopathological Features in Subgroups Variable Lesion Size of Uterine Wall ≥2/3 (n=446, 88.8%) Lesion Size of Uterine Wall <2/3 (n=56, 11.2%) Test Value P Age (years) 43.9±5.2 42.6±5.6 1.777 0.076 BMI (kg/m2) 23.6±2.8 24.1±2.8 −1.337 0.182 Uterus location (n (%)) 1.115 0.572  Anterior 263 (59.0%) 29 (51.8%)  Posterior 167 (37.4%) 25 (44.6%)  Neutral 16 (3.6%) 2 (3.6%) Uterus volume (cm3) 236.9±125.6 185.0±105.0 2.889 0.004 Adenomyosis location (n (%)) 1.662 0.798  Anterior 135 (30.2%) 13 (23.2%)  Posterior 219 (49.1%) 32 (57.1%)  Fundus 33 (7.4%) 5 (8.9%) Left or right lateral 25 (5.6%) 2 (3.6%) Anterior/Posterior/fundus/lateral 34 (7.6%) 4 (7.2%) Adenomyosis volume (cm3) 56.1±55.7 32.3±51.6 3.067 0.003 Subcutaneous fat thickness (mm) 19.2±8.0 20.5±15.3 −0.637 0.527 Distance (mm) 23.9±14.7 25.1±15.7 −0.504 0.614 Serum CA125 (U/mL) 57.9 (31.1, 111.1) 35.1 (16.8, 67.0) −3.236 0.001 Dysmenorrhea before FUAS (n (%)) 2.227 0.136  Yes 343 (76.9%) 38 (67.9%)  No 103 (23.1%) 18 (32.1%) Menorrhagia before FUAS (n (%)) 2.333 0.127  Yes 247 (55.4%) 23 (44.2%)  No 199 (44.6%) 29 (55.8%) Recurrence of symptoms (n (%)) 1.857 0.173  Yes 99 (22.2%) 8 (14.3%)  No 347 (77.8%) 48 (85.7%) Abbreviations : BMI, body mass index; CA125, cancer antigen 125; Distance, distance from the posterior surface of the adenomyosis lesion to the sacrum; FUAS, focused ultrasound ablation surgery. Figure 1 The example of Classification system 4 (red color arrow showed the lesion location based on MRI). The image presented a multi-panel set of pelvic MRI scans illustrating varying degrees of lesion involvement within the uterine wall. Each panel highlighted abnormal regions using red arrows to indicate lesion location and extent. The images were organized to compare internal, external, and combined patterns of involvement, with progression from less extensive to more extensive infiltration across panels. Differences in lesion depth and spread within the uterine structure were visually apparent, emphasizing how the abnormal tissue occupied different proportions of the wall. The grayscale imaging provided anatomical detail, allowing identification of boundaries between normal and affected tissue. This visual arrangement helped demonstrate classification based on lesion distribution and penetration within the uterus, aiding in comparative assessment across cases. MRI panels showing graded uterine wall involvement by lesions with red arrows marking affected regions. Clinicopathological Features in Subgroups Abbreviations : BMI, body mass index; CA125, cancer antigen 125; Distance, distance from the posterior surface of the adenomyosis lesion to the sacrum; FUAS, focused ultrasound ablation surgery. The example of Classification system 4 (red color arrow showed the lesion location based on MRI). Univariate analysis identified younger age, dysmenorrhea, CA125 level, lesion extent ≥2/3, diffuse grayscale changes, and monotherapy as associated with recurrence (all P<0.05). Multivariate logistic regression confirmed CA125 (OR=1.002, 95% CI 1.001–1.004, P=0.012), diffuse grayscale changes (OR=0.632, 95% CI 0.407–0.981, P=0.041), and combination therapy (OR=0.504, 95% CI 0.323–0.785, P=0.002) as independent predictors in the total cohort ( Table 3 ). In the ≥2/3 subgroup, CA125 remained predictive (OR=1.002, 95% CI 1.001–1.004, P=0.013) and combination therapy showed stronger protection (OR=0.553, 95% CI 0.350–0.874, P=0.011) ( Table 4 ). Table 3 Binary Logistic Regression Analysis of Symptom Recurrence in Total Cohort of Patients with Adenomyosis Variable Univariate Multivariate OR 95% CI P OR 95% CI P Lesion size of uterine wall (≥2/3 vs<2/3) 2.336 (1.075~5.079) 0.032 1.855 (0.793~4.338) 0.154 Serum CA125 (U/mL) 1.003 (1.001~1.005) 0.003 1.002 (1.001~1.004) 0.012 T2WI hyper-intensity (yes vs no) 1.090 (0.667~1.78) 0.731 1.054 (0.611~1.819) 0.849 Grayscale change (diffusion vs single) 0.662 (0.444~0.987) 0.043 0.632 (0.407~0.981) 0.041 FUAS combine with GnRH-a/LNG-IUS (yes vs no) 0.515 (0.343~0.773) 0.001 0.504 (0.323~0.785) 0.002 Abbreviations : FUAS, focused ultrasound ablation surgery; CA125, cancer antigen 125; T2WI, T2-weighted magnetic resonance imaging; NPV, non-perfusion volume; GnRH-a, Gonadotropin-releasing hormone agonist; LNG-IUS, Levonorgestrel-releasing Intrauterine System. Table 4 Binary Logistic Regression Analysis of Symptom Recurrence in Subgroups Patients with Adenomyosis Variable Lesion Size of Uterine Wall ≥2/3 Lesion Size of Uterine Wall <2/3 OR 95% CI P OR 95% CI P Serum CA125 (U/mL) 1.002 (1.001~1.004) 0.013 1.010 (0.982~1.038) 0.500 T2WI hyper-intensity (yes vs no) 1.065 (0.601~1.885) 0.830 0.802 (0.122~5.286) 0.819 Grayscale change (diffusion vs single) 0.631 (0.401~0.995) 0.047 0.577 (0.086~3.872) 0.571 FUAS combine with GnRH-a/LNG-IUS (yes vs no) 0.553 (0.350~0.874) 0.011 0.094 (0.009~0.984) 0.048 Abbreviations : FUAS, focused ultrasound ablation surgery; CA125, cancer antigen 125; T2WI, T2-weighted magnetic resonance imaging; NPV, non-perfusion volume; GnRH-a, Gonadotropin-releasing hormone agonist; LNG-IUS, Levonorgestrel-releasing Intrauterine System. Binary Logistic Regression Analysis of Symptom Recurrence in Total Cohort of Patients with Adenomyosis Abbreviations : FUAS, focused ultrasound ablation surgery; CA125, cancer antigen 125; T2WI, T2-weighted magnetic resonance imaging; NPV, non-perfusion volume; GnRH-a, Gonadotropin-releasing hormone agonist; LNG-IUS, Levonorgestrel-releasing Intrauterine System. Binary Logistic Regression Analysis of Symptom Recurrence in Subgroups Patients with Adenomyosis Abbreviations : FUAS, focused ultrasound ablation surgery; CA125, cancer antigen 125; T2WI, T2-weighted magnetic resonance imaging; NPV, non-perfusion volume; GnRH-a, Gonadotropin-releasing hormone agonist; LNG-IUS, Levonorgestrel-releasing Intrauterine System. In the ≥2/3 subgroup, preoperative CA125 predicted recurrence with an AUC of 0.580 (95% CI 0.533–0.626, P<0.001). The optimal cutoff was 57.1 U/mL (sensitivity 60.6%, specificity 58.6%). Using a clinically practical cutoff of 35 U/mL, sensitivity increased to 72.8% (specificity 38.9%) ( Table 5 and Figure 2 ). Table 5 Parameters of Different Cutoff Value of Serum CA125 in Patients with Lesion Size of Uterine Wall ≥2/3 Cutoff value (U/mL) Sensitivity (%) Specificity (%) +LR -LR > 57.1 vs ≤ 57.1 60.6 58.6 1.18 0.71 > 35 vs ≤ 35 72.8 38.9 1.43 0.70 Notes : LR+= positive likelihood ratio (sensitivity/[1-specificity]); LR-= negative likelihood ratio ([1-sensitivity]/specificity). Figure 2 Receiver operating characteristic curve of CA125 predicting symptom recurrence in the ≥2/3 lesion subgroup. A line graph titled CA125 showing a receiver operating characteristic curve predicting symptom recurrence. Parameters of Different Cutoff Value of Serum CA125 in Patients with Lesion Size of Uterine Wall ≥2/3 Notes : LR+= positive likelihood ratio (sensitivity/[1-specificity]); LR-= negative likelihood ratio ([1-sensitivity]/specificity). Receiver operating characteristic curve of CA125 predicting symptom recurrence in the ≥2/3 lesion subgroup. Multivariate Cox regression analysis showed that elevated preoperative CA125 levels were independently associated with earlier symptom recurrence in the total cohort (HR = 1.001, 95% CI: 1.001–1.003, P = 0.015 Table 6 ) and in the subgroup with extensive uterine wall involvement≥2/3(HR = 1.001, 95% CI: 1.000–1.002, P = 0.040 Table 6 ). Kaplan–Meier survival analysis further demonstrated that patients with preoperative CA125 levels >35 U/mL experienced significantly shorter median recurrence-free survival than those with CA125 ≤35 U/mL in the total cohort (38.5 vs 44.5 months, as shown in Figure 3A , P < 0.05). This difference was particularly pronounced in the subgroup with extensive uterine wall involvement (≥2/3), where the high-CA125 group had a median recurrence time of 37.7 months versus 43.9 months (P = 0.001, Figure 3B ). Table 6 Cox Regression Analysis of Symptom Recurrence in Patients with Adenomyosis Variable Total Group Lesion Size of Uterine Wall ≥2/3 OR 95% CI P OR 95% CI P Serum CA125 (U/mL) 1.001 (1.001~1.003) 0.015 1.001 (1.000~1.002) 0.040 T2WI hyper-intensity (yes vs no) 1.065 (0.405~1.081) 0.099 0.792 (0.540~1.161) 0.232 Grayscale change (diffusion vs single) 0.631 (0.401~0.995) 0.179 0.748 (0.450~1.246) 0.265 Abbreviation : CA125, cancer antigen 125. Figure 3 Kaplan–Meier curve of CA125 predicting symptom recurrence, ( A ) showed K-M curve of CA125 predicting symptom recurrence in total cohort, patients with CA125 >35 U/mL had shorter median recurrence-free survival (38.5 vs 44.5 months, P35 U/mL had shorter median recurrence-free survival (37.7 vs 43.9 months, P=0.001). CA125 less than or equal to 35 U/mL; CA125 greater than 35 U/mL; CA125 less than or equal to 35 U/mL censored; CA125 greater than 35 U/mL censored. X‑axis label: Follow‑up time (months). X‑axis range: 0 to 60. Y‑axis label: Cum Non‑recurrence. Y‑axis range: 0.0 to 1.0. Plotted series: two stepwise survival curves with plus‑sign censor markers. Approximate readable curve levels at labeled x ticks. CA125 ≤ 35 U/mL: (0, 1.0), (10, 0.95), (20, 0.90), (30, 0.87), (40, 0.83), (50, 0.55). CA125 > 35 U/mL: (0, 1.0), (10, 0.93), (20, 0.78), (30, 0.70), (40, 0.62), (50, 0.15). Trend comparison: CA125 ≤ 35 U/mL remained higher than CA125 > 35 U/mL across follow‑up; both declined over time with larger late drops near 45 to 52 months. Caption text: A In total cohort. The image B showed a multi‑line Kaplan‑Meier graph titled CA125_A. Legend entries: CA125 ≤ 35 U/mL; CA125 > 35 U/mL; CA125 ≤ 35 U/mL censored; CA125 > 35 U/mL censored. X‑axis label: Follow‑up time (months). X‑axis range: 0 to 60. Y‑axis label: Cum Non‑recurrence. Y‑axis range: 0.0 to 1.0. Plotted series: two stepwise survival curves with plus‑sign censor markers. Approximate readable curve levels at labeled x ticks. CA125 ≤ 35 U/mL: (0, 1.0), (10, 0.95), (20, 0.90), (30, 0.86), (40, 0.80), (50, 0.50). CA125 > 35 U/mL: (0, 1.0), (10, 0.92), (20, 0.80), (30, 0.70), (40, 0.62), (50, 0.12). Trend comparison: CA125 ≤ 35 U/mL remained higher than CA125 > 35 U/mL across follow‑up; both declined over time with a pronounced late drop for CA125 > 35 U/mL near 50 months. Caption text: B Patients with lesion size of uterine wall greater than or equal to 2/3. Two multi-line Kaplan-Meier graphs titled CA125_A predicting symptom recurrence. Cox Regression Analysis of Symptom Recurrence in Patients with Adenomyosis Abbreviation : CA125, cancer antigen 125. Kaplan–Meier curve of CA125 predicting symptom recurrence, ( A ) showed K-M curve of CA125 predicting symptom recurrence in total cohort, patients with CA125 >35 U/mL had shorter median recurrence-free survival (38.5 vs 44.5 months, P35 U/mL had shorter median recurrence-free survival (37.7 vs 43.9 months, P=0.001).

This cross-sectional study identified preoperative serum CA125 as an independent predictive factor for symptomatic recurrence after FUAS in adenomyosis patients with extensive uterine involvement (lesion size ≥2/3 of uterine wall thickness on MRI). The clinically established cutoff of 35 U/mL exhibited a high sensitivity in predicting both recurrence incidence and shorter recurrence-free intervals, suggesting its utility as a practical biomarker for risk stratification in this patient subgroup. Moreover, these findings supported the incorporation of preoperative CA125 assessment, particularly when combined with MRI-based lesion characterization, into clinical decision-making for adenomyosis management. Consistent with previous reports by Sheth et al, 9 our study confirmed that elevated preoperative CA125 levels correlated with larger adenomyotic lesion volumes, particularly in external-type adenomyosis characterized by higher rates of pelvic adhesion and concurrent endometriosis. This patient subgroup typically presented with more pronounced inflammatory activity. Our findings revealed that when uterine wall involvement exceeded ≥2/3 thickness, patients with CA125 >35 U/mL (especially >57.1 U/mL) accompanied by severe dysmenorrhea, 13 T2WI signal abnormalities, and diffuse grayscale changes during FUAS demonstrated significantly higher symptomatic recurrence rates. For patients demonstrating extensive uterine involvement (≥2/3 wall thickness) and elevated CA125 levels (>57.1 U/mL), a comprehensive therapeutic approach was recommended:1) during FUAS, application of maximal safe acoustic energy levels to achieve complete lesion ablation while maintaining appropriate safety margins; 2) implementation of adjuvant medical therapy, with either gonadotropin-releasing hormone agonists (GnRH-a) or a levonorgestrel-releasing intrauterine system (LNG-IUS), to enhance treatment efficacy; 3) for high-risk patients without immediate pregnancy plans, a sequential regimen of 4–6 cycles of GnRH-a therapy followed by LNG-IUS insertion was strongly recommended to optimize the long-term outcomes. These findings demonstrated that FUAS monotherapy might be insufficient for high-risk adenomyosis cases, underscoring the need for comprehensive, individualized treatment strategies incorporating both surgical and medical approaches to minimize the recurrence risk. However, CA125 elevation can occur in various benign and malignant conditions (eg, pregnancy, liver disease, autoimmune disorders). 20 , 21 Thus, false positives should be considered when interpreting results. Building upon our previous findings that Kishi Y ’ s classification system correlated with FUAS effectiveness, 3 , 22 this study advanced the field by demonstrating that classification system 4, when used in combination with preoperative CA125 levels, provided the optimal predictive value for symptom recurrence. At first, the combination of CA125 ≥35 U/mL with MRI-documented lesion extent ≥2/3 uterine wall thickness effectively identified high-risk adenomyosis patients for post-FUAS recurrence (AUC=0.580, 95% CI: 0.533–0.62). This dual-parameter approach significantly improved the preoperative risk assessment compared with either biomarker alone (P<0.01), suggesting the biomarker utility in risk stratification and postoperative surveillance. Second, younger patients presenting with both extensive disease (≥2/3 involvement) and elevated CA125 levels (>57.1 U/mL) were associated with a higher recurrence risk, suggesting a distinct clinical phenotype requiring multimodal therapy, which might be beneficial for the comprehensive preoperative assessment of the optimal patient stratification and treatment planning, like the consideration of combination therapies for high-risk patients with extensive adenomyosis. Third, the predictive power of this combined model stemmed from the role of CA125 as an inflammatory mediator in adenomyosis pathogenesis. Emerging evidence had established inflammation as a pivotal driver for both the initiation and progression of adenomyosis, 23 involving a complex interplay of genetic, hormonal, and inflammatory factors. 24 Serum CA125, a cost-effective and clinically accessible biomarker, was a high-molecular-weight glycoprotein predominantly expressed by coelomic epithelial derivatives in the inflammatory environment. 25 The up-regulation in adenomyosis patients reflected multiple pathological mechanisms, including inflammatory activation. Peritoneal irritation and increased endothelial permeability (often secondary to peritoneal stretching) triggered the substantial release of CA125 into the circulation, causing the increased preoperative level. 7 The elevated CA125 levels might facilitate the ectopic endometrial migration and enhance the myometrial adhesion capacity, clinically manifesting as the increased pain severity and higher recurrence rates, 12 especially in patients with MRI-documented lesion extent ≥2/3 uterine wall thickness. Besides, the reduction of post-FUAS CA125 level correlated with the diminished inflammatory activity, serving as a potential indicator of treatment response and disease burden alleviation. Thus, this multifunctional biomarker not only reflected both the inflammatory milieu and disease activity in adenomyosis, but also provided clinical utility in treatment monitoring and prognosis assessment.

Preoperative CA125 ≥35 U/mL combined with MRI lesion extent ≥2/3 uterine wall involvement may identify adenomyosis patients at high risk of post-FUAS recurrence. The combination of FUAS with GnRH-a and LNG-IUS might reduce recurrence risk. Further multicenter prospective studies are required to confirm these findings.

Although the integrated imaging-biomarker approach supports personalized management of adenomyosis—particularly in identifying candidates who may benefit from combined surgical and medical therapies—several inherent limitations of this study should be acknowledged. First, as a single-center retrospective study, the findings are subject to potential selection bias and may not be generalizable to broader populations. Second, postoperative CA125 levels were not measured, precluding analysis of dynamic changes before and after FUAS and limiting our ability to explore the relationship between CA125 kinetics and symptom recurrence. Additionally, CA125 is known to be elevated in various benign and malignant conditions 20 (eg, pregnancy, liver disease, endometriosis), 20 , 21 and the possibility of false-positive elevations cannot be entirely excluded, which may have influenced the predictive performance. Although the retrospective design does not permit causal inference, the observed association between preoperative CA125 and recurrence offers clinically useful information for risk stratification and postoperative surveillance. Third, despite rigorous follow-up efforts, the retrospective nature of the study led to incomplete data collection, partly due to the exclusion of patients from distant regions who could not attend on-site visits. Fourth, symptom recurrence was assessed based on patient-reported binary outcomes (presence or absence of dysmenorrhea and/or menorrhagia), without standardized severity grading, which may introduce reporting bias. Finally, the predictive model was not validated in an independent external cohort, and its performance may be overestimated. Future multicenter studies incorporating validated tools such as the Numerical Rating Scale (NRS) and including external validation cohorts are warranted to provide more robust evidence regarding the prognostic value of preoperative CA125 in adenomyosis.